Sagimet Biosciences Inc. - 8-K Filing

Sagimet Biosciences priced $107.5M equity offering for Phase 3 acne trial and other programs (Items: 1.01 Entry into a Material Definitive Agreement, 9.01 Financial Statements and Exhibits (d) Exhibits ExhibitNo)

SEC EDGAR ·

Tickers: $SGMT

Read the full article at SEC EDGAR

More Regulatory news